AUS
NZ
UK
CA
USA
IND
GSK PLC (LSE:GSK) has reported promising results for its mRNA-based seasonal flu vaccine. The company has advanced this vaccine to phase III trials following positive outcomes in phase II testing. This comes on the heels of less favorable news regarding an experimental herpes treatment within the vaccine division.
The mRNA vaccine demonstrated effective immune responses against influenza A and B strains in both younger and older populations. It prompted a strong immune reaction, including substantial antibody production, while maintaining an acceptable safety profile.
Tony Wood, Chief Scientific Officer at GSK, highlighted that these initial findings represent a major step forward in the company's mRNA research program. The results support progressing to late-stage development with the goal of introducing a new, top-tier vaccine for enhanced influenza protection.
Earlier in the year, GSK secured a €1.45 billion agreement to gain control over a partnership with Germany’s CureVac, aimed at developing new mRNA vaccines for influenza and COVID-19. This collaboration builds on their joint efforts since 2020 in advancing mRNA vaccine technology.
Unlike traditional vaccines that use whole viruses, bacterial components, or specific viral parts, mRNA vaccines work by instructing cells to produce proteins that can combat diseases. This innovative approach represents a significant evolution in vaccine technology, offering the potential for more effective and targeted immunization strategies.
